loader from loading.io

Cultural Complications Curriculum: Applicability to Surgical Oncology Programs and Practices

Speaking of SurgOnc

Release Date: 02/08/2022

Neuroendocrine Tumor Liver Metastases: Long-Term Follow-up Evaluation of More Than 500 Patients show art Neuroendocrine Tumor Liver Metastases: Long-Term Follow-up Evaluation of More Than 500 Patients

Speaking of SurgOnc

Rick Greene, MD, discusses with Sean Cleary, MD, cytoreductive hepatectomy for neuroendocrine tumor liver metastases; specifically, perioperative outcomes and operative trends, rates and duration of symptomatic relief, and long-term survival and predictors of prognosis. Dr. Cleary is the senior author of, “Neuroendocrine Tumor Liver Metastases: Long-Term Follow-up Evaluation of More Than 500 Patients.” Dr. Cleary is the Bernard and Ryna Langer Chair of the Division of General Surgery in the Department of Surgery at the University of Toronto, Toronto, Canada.

info_outline
Endocrine Therapy for Surgeons: Practical Pearls for Managing Menopausal, Bone Loss and Sexual Adverse Effects show art Endocrine Therapy for Surgeons: Practical Pearls for Managing Menopausal, Bone Loss and Sexual Adverse Effects

Speaking of SurgOnc

Rick Greene, MD, discusses with Anna Weiss, MD, the evidence-based treatments available for the adverse effects of endocrine therapy that can be experienced by breast cancer patients, including clear treatment algorithms for genitourinary syndrome of menopause (GSM), which can be overlooked by providers. Dr. Weiss is the senior author of, “Endocrine Therapy for Surgeons: Practical Pearls for Managing Menopausal, Bone Loss and Sexual Adverse Effects.” Dr. Weiss is Associate Professor of Surgery and Medicine, and Director of the Wilmot Cancer Institute Comprehensive Breast Cancer Program at...

info_outline
Impact of the Histologic Pattern of Residual Tumor After Neoadjuvant Chemotherapy on Recurrence and Survival in Stage I–III Breast Cancer show art Impact of the Histologic Pattern of Residual Tumor After Neoadjuvant Chemotherapy on Recurrence and Survival in Stage I–III Breast Cancer

Speaking of SurgOnc

Rick Greene, MD, and Tari King, MD, FSSO, discuss findings generated from central path review of a large series of patients treated with neoadjuvant chemotherapy and surgery regarding the pattern of residual tumor in the breast and its related prognostic significance. Dr. King is the senior author of, “Impact of the Histologic Pattern of Residual Tumor After Neoadjuvant Chemotherapy on Recurrence and Survival in Stage I–III Breast Cancer.” Dr. Tari A. King is the Anne E. Dyson Professor of Surgery at Harvard Medical School, the chief of the Division of Breast Surgery and the vice chair...

info_outline
Long-Term Survival in Patients Treated with Cytoreduction and Heated Intraperitoneal Chemotherapy for Peritoneal Mesothelioma at a Single High-Volume Center show art Long-Term Survival in Patients Treated with Cytoreduction and Heated Intraperitoneal Chemotherapy for Peritoneal Mesothelioma at a Single High-Volume Center

Speaking of SurgOnc

Rick Greene, MD discusses with Edward A. Levine, MD, long-term survival in patients with malignant peritoneal mesothelioma undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Dr. Levine is the senior author of, “Long-Term Survival in Patients Treated with Cytoreduction and Heated Intraperitoneal Chemotherapy for Peritoneal Mesothelioma at a Single High-Volume Center.” Dr. Levine is Professor, Surgical Sciences - Oncology, Chief of Surgical Oncology at Atrium Wake Forest Health, and Section Editor of the Peritoneal Surface Malignancies section of the Annals of...

info_outline
Exploring the Potential of Artificial Intelligence in Surgery: Insights from a Conversation with ChatGPT show art Exploring the Potential of Artificial Intelligence in Surgery: Insights from a Conversation with ChatGPT

Speaking of SurgOnc

Rick Greene, MD, discusses with Jesse Selber MD, MPH, MHCM, FACS, the use of ChatGPT and explores questions regarding the potential of artificial intelligence (AI) in surgery and its opportunities, challenges, and possible role in surgery. Dr. Selber is the senior author of the article entitled "Exploring the Potential of Artificial Intelligence in Surgery: Insights from a Conversation with ChatGPT.” Dr. Selber is Surgical Service Line Chief and Professor of Plastic Surgery at Corewell Health, East outside of Detroit, Michigan.

info_outline
A Model to Predict Treatment Failure in Patients Undergoing Upfront Surgery for Resectable Colorectal Liver Metastases show art A Model to Predict Treatment Failure in Patients Undergoing Upfront Surgery for Resectable Colorectal Liver Metastases

Speaking of SurgOnc

Rick Greene, MD, discusses with Giammauro Berardi, MD, PhD, FEBS, the outcomes of a large cohort of patients undergoing upfront surgery for resectable colorectal liver metastases (CRLM) to analyze the predictability and probability of early treatment failure using clinicopathological characteristics. Dr. Berardi is author of,  Dr. Berardi is attending at the Department of HPB Surgery and Liver Transplantation of the San Camillo Forlanini Hospital, Rome, Italy, and previous to that was a Surgical Oncology clinical fellow at Memorial Sloan-Kettering Cancer Center, New York NY.

info_outline
Integration of Universal Germline Genetic Testing for All New Breast Cancer Patients show art Integration of Universal Germline Genetic Testing for All New Breast Cancer Patients

Speaking of SurgOnc

Rick Greene, MD, discusses with Julie Culver, MS, LCGC, CCRP,  the implementation of genetic testing for all patients with breast cancer and how this can be incorporated into oncology care. Ms. Culver is author of Julie Culver is the Director of Genetic Counseling at the USC Norris Cancer Hospital and is a Clinical Instructor of Medicine at the USC Keck School of Medicine, Los Angeles, CA. http://doi.org/10.1245/S10434-022-12595-W

info_outline
Is Routine Omentectomy a Necessary Component of Cytoreductive Surgery and HIPEC? show art Is Routine Omentectomy a Necessary Component of Cytoreductive Surgery and HIPEC?

Speaking of SurgOnc

Rick Greene, MD, discusses with Joel Baumgartner, MD, the rate of occult omental metastases in patients undergoing cytoreductive surgery-HIPEC for peritoneal surface malignancy. Dr. Baumgartner is author of, Dr. Baumgartner is Associate Professor in the Department of Surgery, UC San Diego School of Medicine, San Diego, CA. http://doi.org/10.1245/S10434-022-12714-7

info_outline
Phase III Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection for Colon Cancer: An Intergroup Trial of the ECOG-ACRIN Cancer Research Group (E1292) show art Phase III Prospectively Randomized Trial of Perioperative 5-FU After Curative Resection for Colon Cancer: An Intergroup Trial of the ECOG-ACRIN Cancer Research Group (E1292)

Speaking of SurgOnc

Rick Greene, MD, discusses with Margaret Kemeny, MD, the results of a phase III randomized trial that evaluated the effect of perioperative fluorouracil on overall survival in colon cancer. Dr. Kemeny is author of, Dr. Kemeny is Director of New York's Cancer Center of Excellence at Queens Cancer Center of NYC Health+Hospitals/Queens and Professor of Surgery at the Icahn School of Medicine at Mount Sinai.

info_outline
Genetic Testing Among Patients with High-Risk Breast, Ovarian, Pancreatic, and Prostate Cancers show art Genetic Testing Among Patients with High-Risk Breast, Ovarian, Pancreatic, and Prostate Cancers

Speaking of SurgOnc

Rick Greene, MD, discusses with Meghan R. Flanagan, MD, MPH, the results of a retrospective population-based study about genetic testing among patients with breast, ovarian, pancreatic and prostate cancers. Dr. Flanagan is author of, Dr. Flanagan is Assistant Professor of Surgery at the University of Washington School of Medicine, Seattle, WA. http://doi.org/10.1245/S10434-022-12755-Y

info_outline
 
More Episodes

In this episode of Speaking of SurgOnc, Rick Greene, MD and Lesly A. Dossett, MD, discuss meeting the needs of an increasingly culturally and racially diverse patient population, as well as support and recruitment of a surgical oncology workforce that better represents all minority groups. Dr. Dossett is author of the article, “Cultural Complications Curriculum: Applicability to Surgical Oncology Programs and Practices.”

Dr. Dossett is Associate Professor of Surgery, Chief of the Division of Surgical Oncology and Vice Chair for Faculty Life in the Department of Surgery at the University of Michigan, Ann Arbor, MI.